Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT

Cytokine

Volumn 57, Issue 2, 2012, Pages 294-299

  Mabilleau, Guillaume ^a,b   Pascaretti Grizon, Florence ^a   Baslé, Michel Félix ^a   Chappard, Daniel ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bone resorption; Osteoclasts; RANKL; TNF alpha; Vertical scanning profilometry

Indexed keywords

HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANALYTIC METHOD; ARTICLE; CELL CULTURE; CELL NUCLEUS; CELL SIZE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSCOPY; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VERTICAL SCANNING PROFILOMETRY;

BONE RESORPTION; CELL NUCLEUS; CELL NUCLEUS SIZE; HUMANS; INTERLEUKIN-1; MODELS, BIOLOGICAL; OSTEOCLASTS; RANK LIGAND; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855454447     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.014     Document Type: Article

References (39)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990, 87:7260-7264.
3. Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996, 137:4058-4060.
4. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
5. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
6. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
7. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
8. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
9. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
10. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
11. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
12. Dobnig H., Hofbauer L.C., Viereck V., Obermayer-Pietsch B., Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006, 17:693-703.
13. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
14. Tamada K., Shimozaki K., Chapoval A.I., Zhai Y., Su J., Chen S.F., et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000, 164:4105-4110.
15. Tamada K., Shimozaki K., Chapoval A.I., Zhu G., Sica G., Flies D., et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000, 6:283-289.
16. Body J.J., Lipton A., Gralow J., Steger G.G., Gao G., Yeh H., et al. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 2010, 25:440-446.
17. Clezardin P., Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 2007, 24:599-608.
18. Edwards J.R., Sun S.G., Locklin R., Shipman C.M., Adamopoulos I.E., Athanasou N.A., et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006, 54:1451-1462.
19. Kim N., Kadono Y., Takami M., Lee J., Lee S.H., Okada F., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005, 202:589-595.
20. Manicourt D.H., Poilvache P., Van Egeren A., Devogelaer J.P., Lenz M.E., Thonar E.J. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000, 43:281-288.
21. Pierer M., Brentano F., Rethage J., Wagner U., Hantzschel H., Gay R.E., et al. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology (Oxford, England) 2007, 46:1063-1070.
22. Pascaretti-Grizon F., Mabilleau G., Basle M.F., Chappard D. Measurement by vertical scanning profilometry of resorption volume and lacunae depth by osteoclasts on dentine slices. J Microsc 2011, 241:147-152.
23. Mabilleau G., Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE 2009, 4:e4173.
24. Mabilleau G., Petrova N.L., Edmonds M.E., Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008, 51:1035-1040.
25. Bataille R., Chappard D., Baslé M.F. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 1996, 87:4762-4769.
26. Bataille R., Chappard D., Baslé M. Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 1995, 90:721-724.
27. Rossi J.F., Chappard D., Marcelli C., Laplante J., Commes T., Baldet P., et al. Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. Br J Haematol 1990, 76:469-475.
28. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000, 343:1594-1602.
29. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
30. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
31. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev 2009, 5:667-676.
32. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8:21-30.
33. Ishida S., Yamane S., Nakano S., Yanagimoto T., Hanamoto Y., Maeda-Tanimura M., et al. The interaction of monocytes with rheumatoid synovial cells is a key step in LIGHT-mediated inflammatory bone destruction. Immunology 2009, 128:e315-e324.
34. Ishida S., Yamane S., Ochi T., Nakano S., Mori T., Juji T., et al. LIGHT induces cell proliferation and inflammatory responses of rheumatoid arthritis synovial fibroblasts via lymphotoxin beta receptor. J Rheumatol 2008, 35:960-968.
35. Kang Y.M., Kim S.Y., Kang J.H., Han S.W., Nam E.J., Kyung H.S., et al. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. Arthritis Rheum 2007, 56:1106-1117.
36. Kim W.J., Kang Y.J., Koh E.M., Ahn K.S., Cha H.S., Lee W.H. LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of pro-inflammatory cytokines and MMP-9 in macrophages. Immunology 2005, 114:272-279.
37. Giuliani N, Colla S, Rizzoli V, Barille-Nion S, Bataille R. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? Cancer Res 2004;64:772-3; author reply 4-5.
38. Rossi J.F., Bataille R., Chappard D., Alexandre C., Janbon C. B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases. Am J Med 1987, 83:10-16.
39. Josselin N., Libouban H., Dib M., Ifrah N., Legrand E., Basle M.F., et al. Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy. Pathol Oncol Res 2009, 15:65-72.